GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Deferred Policy Acquisition Costs

SK Bioscience Co (XKRX:302440) Deferred Policy Acquisition Costs


View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


SK Bioscience Co (XKRX:302440) Business Description

Industry
Traded in Other Exchanges
N/A
Address
310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.